000			04026nam a22006017a 4500
008			190118s20192019 xxu||||| |||| 00| 0 eng d
022			_a2047-2404
024			_a10.1093/ehjci/jey210 [doi]
024			_a5262257 [pii]
040			_aOvid MEDLINE(R)
099			_a30590578
245			_aImpact of procedural characteristics on coronary vessel wall healing following implantation of second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary artery lesions: an optical coherence tomography analysis.
251			_aEuropean heart journal cardiovascular Imaging. 20(8):916-924, 2019 Aug 01.
252			_aEur Heart J Cardiovasc Imaging. 20(8):916-924, 2019 Aug 01.
252			_zEur Heart J Cardiovasc Imaging. 2018 Dec 26
253			_aEuropean heart journal cardiovascular Imaging
260			_c2019
260			_fFY2020
265			_saheadofprint
265			_sppublish
266			_d2019-01-18
268			_aEuropean heart journal cardiovascular Imaging. 2018 Dec 26
269			_fFY2019
520			_aAims: Second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) is an alternative novel device for treating coronary lesions. However, the relationship between in-scaffold dimensions after implantation of DREAMS 2G and vessel healing and luminal results at follow-up is unknown. The aim of this study is, therefore, to investigate whether the expansion index after implantation of DREAMS 2G as assessed by optical coherence tomography (OCT) impacts late luminal status and healing of the vessel wall.
520			_aConclusion: Excellent in vivo healing process after implantation of DREAMS 2G was observed at 6 months. We found that higher expansion indices were associated with higher in-scaffold LVL at 6 months assessed by OCT.
520			_aMethods and results: This study comprises of a total 65 out of 123 patients who were enrolled in the BIOSOLVE-II trial. We assessed both qualitative and quantitative OCT findings and the expansion index of DREAMS 2G after implantation frame by frame using OCT. Expansion index was defined as minimum scaffold area/mean reference lumen area. The over-expansion group was also defined with expansion index >1.0. The total number of analysed frames at post- procedure and 6-month follow-up was 8243 and 8263 frames, respectively. At 6-month follow-up, in-scaffold healing was documented by the reduction of 82% in dissections, 93% in attached intra-luminal mass (ILM), 65% in non-attached ILM, and 76% in jailed side branch. The over-expansion group had significantly greater in-scaffold luminal volume loss (LVL) compared with the non-over-expansion group [over- expansion: 35.0 (18.5-52.1) mm3 vs. non-over-expansion: 21.0 (11.6- 37.9) mm3, P = 0.039].
546			_aEnglish
650			_a*Coronary Vessels/dg [Diagnostic Imaging]
650			_a*Drug-Eluting Stents
650			_a*Tomography, Optical Coherence
650			_a*Wound Healing
650			_aAbsorbable Implants
650			_aAdult
650			_aAged
650			_aEquipment Design
650			_aFemale
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aProspective Studies
650			_aSirolimus/ad [Administration & Dosage]
651			_aMedStar Heart & Vascular Institute
657			_aJournal Article
700			_aGarcia-Garcia, Hector M
700			_aHideo-Kajita, Alexandre
700			_aKuku, Kayode
700			_aOzaki, Yuichi
700			_aWaksman, Ron
790			_aAbizaid A, Christiansen EH, Dijkstra J, Escaned J, Garcia-Garcia HM, Haude M, Hideo-Kajita A, Ince H, Kuku KO, Lemos PA, Ozaki Y, Tolg R, von Birgelen C, Waksman R, Wijns W
856			_uhttps://dx.doi.org/10.1093/ehjci/jey210 _zhttps://dx.doi.org/10.1093/ehjci/jey210 _zhttps://dx.doi.org/10.1093/ehjci/jey210
856			_uhttps://dx.doi.org/10.1093/ehjci/jey210 _zhttps://dx.doi.org/10.1093/ehjci/jey210 _zhttps://dx.doi.org/10.1093/ehjci/jey210
942			_cART _dArticle
999			_c4017 _d4017